bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group Study

Journal of Clinical Oncology

Volumn 15, Issue 5, 1997, Pages 1916-1922

  Elledge, R M ^a   Green, S ^a   Howes, L ^a   Clark, G M ^a   Berardo, M ^a   Allred, D C ^a   Pugh, R ^a   Ciocca, D ^a   Ravdin, P ^a   O'Sullivan, J ^a   Rivkin, S ^a   Martino, S ^a   Osborne, C K ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0030951877     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.5.1916     Document Type: Article

References (32)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15, 1992
2. Bezwoda W, Esser J, Dansey R, et al: The value of estrogen and progesterone receptor determinations in advanced breast cancer. Cancer 68:867-872, 1991
3. Lu P, Lu Q, Rughetti A, et al: bcl-2 overexpression inhibits cell death and promotes the morphogenesis, but not tumorigenesis of human mammary epithelial cells. J Cell Biol 129:1363-1389, 1995
4. Kyprianou N, English H, Davidson N, et al: Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51:162-166, 1991
5. Wärri AM, Huovinen RL, Laine AM, et al: Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst 85:1412-1418, 1993
6. Perry R, Kang Y, Greaves B: Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol 2:238-245, 1995
7. Yonish-Rouach E, Resnitsky D, Lotem J, et al: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345-347, 1991
8. Ramqvist T, Magnusson K, Wang Y, et al: Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene 8:1495-1500, 1993
9. 1. Proc Natl Acad Sci USA 89:2759-2763, 1992
10. Knabbe C, Lippman M, Wakefield L, et al: Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417-428, 1987
11. Ravdin P, Green S, Door T, et al: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. J Clin Oncol 10:1284-1291, 1992
12. Krajewski S, Blomqvist C, Franssila K, et al: Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55:4471-4478, 1995
13. Hellemans P, van Dam PA, Weyler J, et al: Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 72:354-360, 1995
14. Joensuu H, Pylkkanen L, Toikkanen S: bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145:1191-1198, 1994
15. Hurlimann J, Larrinaga B, Vala D: bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch 426:163-168, 1995
16. Silvestrini R, Veneroni S, Daidone MG, et al: The bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86:499-504, 1994
17. Gee J, Robertson J, Ellis I, et al: Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59:619-628, 1994
18. Thor A, Moore D, Edgerton S, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992
19. Allred D, Clark G, Elledge R, et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993
20. Gasparini G, Weidner N, Bevilacqua P, et al: Tumor microvessel density, p53 expression, tumor size and perilymphatic vessel invasion are relevant prognostic markers in node-negative breast cancer. J Clin Oncol 12:454-466, 1994
21. Lowe S, Ruley H, Jacks T, et al: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993
22. Lowe S, Bodis S, McClatchey A, et al: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994
23. Rusch V, Klimstra D, Venkatraman E, et al: Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55:5038-5042, 1995
24. El Rouby S, Thomas A, Costin D, et al: p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452-3459, 1993
25. Hawkins D, Demers G, Galloway D: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56:892-898, 1996
26. Righetti S, Della Torre G, Pilotti S, et al: A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56:689-693, 1996
27. Osborne C, Boldt D, Estrada P: Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res 44:1433-1439, 1984
28. Elledge R, Lock-Lim S, Allred D, et al: p53 mutation and tamoxifen resistance in breast cancer. Clin Cancer Res 1:1203-1208, 1995
29. Leek R, Kaklamanis L, Pezzella F, et al: bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumors and in situ cancer. Br J Cancer 69:135-139, 1994
30. Gasparini G, Barbareschi M, Doglioni C, et al: Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1:189-198, 1995
31. Bhargava V, Kell D, van de Rijn M, et al: bcl-2 immunoreactivity in breast carcinoma correlated with hormone receptor positivity. Am J Pathol 145:535-540, 1994
32. Berardo M, de Moor C, Clark GM, et al: bcl-2 expression in node-positive breast cancer. Breast Cancer Res Treat 37:37, 1996 (abstr)